The meeting of the Advisory Committee on Vaccines (ACV).
The committee provided advice on two applications:
- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Comirnaty; active ingredient Tozinameran; sponsor Pfizer Australia Pty Ltd) that had been under evaluation from October 2021
- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Vaxzevria; active ingredient ChAdOx-1-S; sponsor AstraZeneca Pty Ltd) that had been under evaluation from November 2021.
Members
Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.
-
Meeting statementsAdvisory Committee on Vaccines, Meeting 30, 14 January 2022